Dive into the archives.
- Facet Biotech Announces Daclizumab MS Program to Advance
Aug 03, 2009 16:30 ET
REDWOOD CITY, CA–(Marketwire – August 3, 2009) – Facet Biotech Corporation today announced its decision, along with its partner Biogen Idec, to continue planning for the phase 3 trial of daclizumab high-yield process (DAC HYP) in multiple sclerosis (MS). The company plans to request a Special Protocol Assessment from [...]
- Daclizumab and Interferon: Next Wave Combination Therapy?
Studies are ongoing. This post isn’t hot off the press…
- Daclizumab shows Promise in Phase II Trial
Daclizumab Shows Promise in Phase II Trial for MS
Just over a year ago, PDL Pharmaceuticals partnered with MS giant Biogen (Avonex, Tysabri) to bring a drug known as daclizumab through trials for MS. Daclizumab is today used for the prevention of kidney transplant rejection, under the marketing name Zenapax (r). The partnership seems to be [...]
